ES2528348T3 - Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna - Google Patents

Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna Download PDF

Info

Publication number
ES2528348T3
ES2528348T3 ES12192951.7T ES12192951T ES2528348T3 ES 2528348 T3 ES2528348 T3 ES 2528348T3 ES 12192951 T ES12192951 T ES 12192951T ES 2528348 T3 ES2528348 T3 ES 2528348T3
Authority
ES
Spain
Prior art keywords
treatment
pharmaceutical preparation
benign prostatic
bromelain
prostatic hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12192951.7T
Other languages
English (en)
Inventor
Lucia Desser
Bernhard Lotz
Thomas Mohr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volopharm GmbH
Original Assignee
Volopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volopharm GmbH filed Critical Volopharm GmbH
Application granted granted Critical
Publication of ES2528348T3 publication Critical patent/ES2528348T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Preparación farmacéutica que comprende al menos dos proteasas para su uso en el tratamiento de la hipertrofia/hiperplasia prostática benigna, en la que la preparación es administrada por vía oral y las al menos dos proteasas son seleccionadas del grupo que consiste en bromelaína, papaína y ficina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
E12192951
20-01-2015
Tabla 2: Inhibición de la formación de tubo en % en HUVEC en presencia de VEGF. Los resultados se muestran como % de inhibición de la formación de tubo, siendo 0 % la formación de tubo en las muestras tratadas sólo con VEGF.
Bromelaína
Natoquinasa Papaína % inhibición de la formación de tubo
75,00 %
25,00 % 0,00 % 98,11 %
16,67 %
16,67 %
66,67 % 93,52 %
25,00 %
25,00 %
50,00 % 87,75 %
0,00 %
75,00 % 25,00 % 87,42 %
75,00 %
0,00 % 25,00 % 86,34 %
25,00 %
0,00 % 75,00 % 83,77 %
16,67 %
66,67 % 16,67 % 83,65 %
50,00 %
0,00 % 50,00 % 82,73 %
0,00 %
50,00 % 50,00 % 80,01 %
0,00 %
25,00 % 75,00 % 78,26 %
33,33 %
33,33 %
33,33 %
74,14 %
25,00 %
75,00 % 0,00 % 61,57 %
50,00 %
25,00 % 25,00 % 47,78 %
0,00 %
0,00 %
100,00 % 39,86 %
5 La Tabla 2 muestra las longitudes de tubo expresadas como % de inhibición de la formación de tubo. Los resultados indican claramente que:
1.
La formación del tubo es inhibida por mezclas de bromelaína, natoquinasa y papaína;
2.
La combinación de bromelaína, natoquinasa y papaína tiene un efecto mayor que los fármacos solos.
La Figura 3(a) muestra la combinación bromelaína 25 %, natoquinasa 50 % y papaína 25 %. (B) muestra el control
10 tratado con VEGF. Mientras que en el control de VEGF es visible un patrón estrecho de tubos formados (flechas), la muestra tratada con enzima muestra amplias áreas sin formación de tubo que indican actividad antiangiogénica del cóctel de enzimas.
Ejemplo 3:
La influencia de preparaciones que comprenden bromelaína en combinación con otras enzimas sobre las células
15 endoteliales de próstata humana (HProsEC) se ha analizado de forma análoga al ejemplo 2, con modificaciones menores. Brevemente, las células se privaron de nutrientes durante 24 horas en medio basal endotelial-2 (MV) (Lonza, Verviers) suplementado con ácido ascórbico e hidrocortisona. Las células se sembraron a una densidad de
10.000 por pocillo en microplacas de titulación de 96 pocillos recubiertas con Matrigel y se incubaron en ausencia o presencia de 5 ng de VEGF/ml con combinaciones de enzimas (bromelaína 100 % o enzima 50 % y bromelaína 20 50 % a 12,5 μg/ml total). Después de 6 horas, los tubos se fotografiaron y se midieron usando el software ImageJ (Instituto Nacional de Salud, Bethesda, EE.UU.). Se han obtenido los siguientes resultados: enzima + bromelaína % inhibición del tubo Formación gen enzima 25 % Inhibición de formación de tubos
enzima + bromelaína Brinasa 21,00 % 81,00 %
11
imagen10
imagen11

Claims (1)

  1. imagen1
ES12192951.7T 2007-12-03 2008-12-03 Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna Active ES2528348T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0196207A AT506095A1 (de) 2007-12-03 2007-12-03 Verwendung von proteasen
AT19622007 2007-12-03

Publications (1)

Publication Number Publication Date
ES2528348T3 true ES2528348T3 (es) 2015-02-09

Family

ID=40404976

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12192951.7T Active ES2528348T3 (es) 2007-12-03 2008-12-03 Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna

Country Status (11)

Country Link
US (1) US8231870B2 (es)
EP (2) EP2224948A1 (es)
JP (1) JP2011505385A (es)
AT (1) AT506095A1 (es)
CA (1) CA2705986C (es)
DK (1) DK2559439T3 (es)
ES (1) ES2528348T3 (es)
MX (1) MX2010005629A (es)
PL (1) PL2559439T3 (es)
RU (1) RU2485971C2 (es)
WO (1) WO2009070818A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI482629B (zh) * 2008-07-01 2015-05-01 Tobishi Pharmaceutical Co 下泌尿道疾病治療劑及下泌尿道症狀改善劑
WO2010029453A1 (en) * 2008-09-10 2010-03-18 Pt.Dexa Medica Composition of thrombolytic agent and anti thrombosis and also its production method
WO2012104241A1 (de) 2011-01-31 2012-08-09 LUCOLAS-M.D. Ltd Kombinationen von aromatase inhibitoren und antioxidanzien
CA2835664C (en) 2011-05-12 2019-02-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
BR112014027995A2 (pt) * 2012-05-11 2017-06-27 Smith & Nephew Inc uso de seaprose para remover biopelícula bacteriana
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
ITTO20121050A1 (it) 2012-12-06 2014-06-07 Giuseppe Carpignoli Sostanze vegetali ad effetto curativo
US10086053B2 (en) 2012-12-06 2018-10-02 Giuseppe CARPIGNOLI Therapeutic vegetable substances
ES2773296T3 (es) * 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
EP3193629B1 (en) * 2014-08-25 2023-01-25 Anatara Lifesciences Limited Anti-diarrhea formulation which avoids antimicrobial resistance
EP3490588A1 (en) 2016-07-27 2019-06-05 Smith&Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
IT201600081379A1 (it) * 2016-08-03 2018-02-03 Neilos S R L Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
EP3573622B1 (en) 2017-01-30 2023-10-18 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
JP7207878B2 (ja) * 2018-06-27 2023-01-18 小林製薬株式会社 ナットウキナーゼを含む食品
JP7207877B2 (ja) * 2018-06-27 2023-01-18 小林製薬株式会社 ナットウキナーゼを含む食品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1003981A1 (en) 1989-01-27 1998-11-13 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
JPH05229983A (ja) * 1992-02-21 1993-09-07 Sankyo Co Ltd レトロジヒドロカルコン化合物
DE4305460C2 (de) 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
JP3978250B2 (ja) * 1996-08-16 2007-09-19 株式会社フジモト・コーポレーション テストステロン５α−リダクターゼ阻害剤
US20010025059A1 (en) * 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
ZA200002342B (en) 2000-05-12 2001-01-11 Pharmachoice Healthcare Propri Nutritional supplement.
EP1443954B1 (en) 2001-10-26 2010-11-24 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
WO2004026335A1 (en) * 2002-09-19 2004-04-01 Santana Cristiano Alberto Ribe Pharmaceutical composition comprising carriers for products
LV13161B (en) * 2004-02-16 2005-07-20 Maris Skromanis Proteolytic pharmaceutical composition
US20060024385A1 (en) 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
US7758594B2 (en) 2005-05-20 2010-07-20 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
RU2306145C1 (ru) * 2006-03-28 2007-09-20 Олег Викторович Бейдик Средство для лечения хронического простатита

Also Published As

Publication number Publication date
EP2224948A1 (en) 2010-09-08
RU2485971C2 (ru) 2013-06-27
AT506095A1 (de) 2009-06-15
RU2010127336A (ru) 2012-01-10
EP2559439A1 (en) 2013-02-20
MX2010005629A (es) 2010-08-18
WO2009070818A1 (en) 2009-06-11
EP2559439B1 (en) 2014-11-26
PL2559439T3 (pl) 2015-04-30
JP2011505385A (ja) 2011-02-24
CA2705986C (en) 2017-06-13
US20100254968A1 (en) 2010-10-07
US8231870B2 (en) 2012-07-31
CA2705986A1 (en) 2009-06-11
DK2559439T3 (en) 2014-12-08

Similar Documents

Publication Publication Date Title
ES2528348T3 (es) Preparación farmacéutica para el tratamiento de la hiperplasia prostática benigna
Leach et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
Laporte et al. Airway proteases: an emerging drug target for influenza and other respiratory virus infections
Du et al. Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
Donadelli et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine
Youn et al. Celastrol ameliorates HIV-1 Tat-induced inflammatory responses via NF-kappaB and AP-1 inhibition and heme oxygenase-1 induction in astrocytes
Victor et al. SARS-CoV-2 triggers DNA damage response in Vero E6 cells
Madhyastha et al. MicroRNA signature in diabetic wound healing: promotive role of miR‐21 in fibroblast migration
Dong et al. Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1
Krieg et al. Mono-ADP-ribosylation by PARP10 inhibits Chikungunya virus nsP2 proteolytic activity and viral replication
DK1649017T4 (da) Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer
Malami et al. Crude extracts, flavokawain B and alpinetin compounds from the rhizome of alpinia mutica induce cell death via UCK2 enzyme inhibition and in turn reduce 18S rRNA biosynthesis in HT-29 cells
Garcia et al. The development of anti-inflammatory drugs for infectious diseases
Zhao et al. Gene expression profiling identifies the novel role of immunoproteasome in doxorubicin-induced cardiotoxicity
Chen et al. Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy
Hsin et al. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells
Ji et al. Inhibition of invasion and metastasis of human liver cancer HCCLM3 cells by portulacerebroside A
Huang et al. Ellagic acid, the active compound of Phyllanthus urinaria, exerts in vivo anti‐angiogenic effect and inhibits MMP‐2 activity
Mostafa et al. Beyond acute infection: molecular mechanisms underpinning cardiovascular complications in long COVID
Krieg et al. Mono-ADP-ribosylation by ARTD10 restricts Chikungunya virus replication by interfering with the proteolytic activity of nsP2
WO2015085904A1 (zh) 禽流感病毒miRNA及其鉴定、检测和应用
Jiang et al. Cardioprotection and matrix metalloproteinase-9 regulation of salvianolic acids on myocardial infarction in rats
WO2023170187A1 (en) INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
Wang et al. Impact of human airway epithelial cellular composition on SARS-CoV-2 infection biology
Shirkavand et al. Solanum nigrum anticancer effect through epigenetic modulations in breast cancer cell lines